Organisation › Details

Array BioPharma Inc. (Nasdaq: ARRY)

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions. Novartis began Phase 3 trials evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and in patients with BRAF-mutant melanoma in October 2013. In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013. AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and began a Phase 3 trial in patients with non-small cell lung cancer in October 2013. Two other wholly-owned drugs, ARRY-520 and ARRY-614, are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. *

 

Period Start 2003-06-01 existent
Products Industry drug discovery technology
  Industry 2 MEK inhibitor
Person Person Squarer, Ron (Array BioPharma 201511 CEO)
     
Region Region Boulder, CO
  Country United States (USA)
  Street 3200 Walnut Street
  City 80301 Boulder, CO
  Tel +1-303-381-6600
    Address record changed: 2008-12-07
     
Basic data Employees n. a.
     
    * Document for �About Section�: AstraZeneca plc. (10/22/13). "Press Release: AstraZeneca Initiates Phase III Clinical Programme for Selumetinib, a Treatment in Development for Patients with Advanced or Metastatic Non-small Cell Lung Cancer".
     
   
Record changed: 2019-06-25

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 650x99px

More documents for Array BioPharma Inc. (Nasdaq: ARRY)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top